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ABSTRACT
Alzheimer’s disease is the sixth leading cause
of death in the United States. The leading
hypothesis to explain the prevalence of the
disease in the brain is the aggregation of
Amyloid Beta peptides in the brain, which
form senile plaques and suppress neuronal
function. Selective estrogen receptor
modulators (SERMs) have been found to
provide protective effects against the
neurotoxic effects of Amyloid Beta. This
experiment was conducted in two distinct
phases: the experimental phase and the
literature review phase. The experimental
phase sought to determine if Amyloid Beta
was neurotoxic to SH-SY5Y neuroblastoma
cells, and if STX—an SERM—was able to
rescue cell viability after exposure to
Amyloid Beta toxicity. During the literature
review phase, potential pathways already
described in the literature were identified,
which might be able to account for how STX
was able to rescue cell viability after
exposure to Amyloid Beta toxicity. Amyloid
Beta was found to have a significant toxic
effect on cell viability when compared to a
control assay of cells grown in DMSO. STX,
however, was not found to have a significant
rescue effect against Amyloid Beta toxicity.
The literature review identified several
pathways that were likely candidates for
neuroprotection, including MAPK, ERK1,
ERK2, and PI3K. The future direction of this
experiment would be to determine if STX is
as effective at providing neuroprotection
against Amyloid Beta as previously
suggested by similar experiments. the next
stage of investigation would then be to inhibit
different pathways that have been identified
as possible pathways for neuroprotection.

INTRODUCTION
Alzheimer’s disease is a progressive brain
disorder that causes impairment in memory
and thinking skills (1). It was first described
by Dr. Alois Alzheimer in 1906, who noted
memory loss, paranoia, and psychological
changes in his patient. Today, Alzheimer’s
disease is the sixth leading cause of death in
the United States (2). The factors that lead to
Alzheimer’s disease are still unknown,
though there are many hypotheses which
seek to explain the etiology of cognitive
impairments associated with the disorder.
One of the leading explanations is the
Amyloid Cascade hypothesis, proposed by
J.A. Hardy and G.A. Higgins in 1992.
Amyloid precursor protein (APP) is
expressed by neuronal cells and extraneuronal tissues. Hardy and Higgins argue
that the proteolytic cleavage of the membrane
glycoprotein amyloid precursor protein into
neurotoxic amyloid beta-peptide (Amyloid 𝛽)
fragments was the cause of the cellular death
process in the central nervous system (3).
In the brain, APP is expressed in three
isoforms: APP695, APP751, and APP770.
APP695 is the most abundant isoform in
neurons and is expressed at relatively high
levels (4). As mentioned previously, APP is a
membrane-bound glycoprotein. It is
processed by membrane bound aspartic
proteinases: 𝛼 and 𝛽 secretases. Each of the
products generated by these proteinases is
processed by 𝛾 secretase and the fragments
are secreted into the cytoplasm. When the
Amyloid 𝛽 domain is processed by 𝛼
secretase, it is cleaved within the Amyloid 𝛽
domain, between residues Lys16 and Leu17;
this is referred to as the non-amyloidogenic
pathway, as it inhibits the generation of intact
Amyloid 𝛽 peptides. When processed by 𝛽
secretase, it is cleaved at Asp1, which is
referred to as the amyloidogenic pathway, as
it forms intact Amyloid 𝛽 peptides (40-42

amino acids long) that are released into the
cytosol. These peptides will frequently
aggregate in the brain and cause the
development of senile plaques (5).
Research into the function of APP secretases,
specifically 𝛾 secretase, has been of interest
to many investigators. By understanding this
mechanism, it is though that we could stop
the production and release of Amyloid 𝛽
peptide, which would prevent plaque
formation all together. Unfortunately, 𝛾
secretase plays a critical role in the cleavage
of other membrane proteins, such as the
Notch1 receptor. Because of this, research
into alternative methods of neuroprotection
from Amyloid 𝛽 peptide is necessary (6).
Estrogens have been shown to have
neuroprotective effects against brain
ischemia, as well as reduce memory
impairment after an ischemic event (7). This
makes estrogen a compelling compound of
study for other conditions that cause
cognitive impairment (7,8). There are
significant risks, however, associated with
17-𝛽 estradiol (E2) treatments; possible side
effects include but are not limited to:
cardiovascular disease, thrombosis, cerebral
vascular accident, and hormone-sensitive
cancers, among others. Selective estrogen
receptor modulators (SERMs) are synthetic
or natural compounds that provide the
positive neuroprotective effects of estrogen
without the negative side effects. STX is one
example of a SERM. STX is able to bind to
the G protein coupled estrogen receptor GqmER in the plasma membrane instead of the
nuclear estrogen receptors. This eliminates
the negative transcriptional responses
generated by E2 that lead to negative side
effects (9).
Building on the research developed by Gray
et al. (9), my research will seek to understand
the pathway that produces the protective
effects of STX against Amyloid 𝛽 toxicity.
My project will be undertaken through a

mixed methodology of primary research and
literature review. In the research phase of my
experiment, I will establish that Amyloid 𝛽is
toxic to SH-SY5Y neuroblastoma cells,
which I will use as my cell culture assay of
amyloid toxicity (9). My literature review
will be focused on previous research
conducted on the different signaling
mechanisms of STX in the cell. This
combined approach will address my research
question: what is the pathway that provides
STX its neuroprotective abilities against the
harmful effects of Amyloid 𝛽?
METHODOLOGY
Experimental phase
SH-SY5Y neuroblastoma cells were cultured
in DMEM/F12 medium (GIBCO/Life
Technologies) supplemented with 10% FBS
and 1% penicillin-streptomycin (SigmaAldrich). Cells were plated in 15,000 cells
per well in 96 well plates to assess cell
viability. Three days after plating, the cells
were washed with phosphate-buffered saline
(PBS; Sigma-Aldrich) and switched to
serum-free DMEM/F12 medium containing
1% N-2 growth supplement (GIBCO/Life
Technologies) and 100nM STX (synthesized
by our colleague Dr. Martin Kelly, Dept of
Physiology and Pharmacology at Oregon
Health and Science University). The next day,
the cells were treated with 50 µM oligomeric
A𝛽 1-42 (prepared using the methods described
by Stine et al (10)) and incubated at 37°C for
72 hours. Cell viability was assessed 48 hours
after incubation period using a Bio-Rad
xMark microplate spectrophotometer.
Literature review phase
The effects of STX on G-protein coupled
receptors (GPCRs) will be the focus of this
study. Articles of focus will be peer reviewed
journal articles that address the effects of
STX on two different membrane estrogen
receptors—G-protein coupled receptor 30

(GPR30) and Gq-coupled membrane
estrogen receptor (Gq-mER)—specifically
with regards to the intracellular signaling
cascades that are engaged, following their
activation.
RESULTS AND DISCUSSION
Experimental phase
In this experiment, Amyloid 𝛽 toxicity was
evaluated after SH-SY5Y cells were treated
with A𝛽 1-42 and allowed to incubate for 72
hours. When cells treated with A𝛽 1-42 were
compared to cells treated with DMSO, cell
viability was found to be significantly
decreased (Figure 1). From these results, it
was determined that 50 µM oligomeric A𝛽 142 was found to be a sufficient concentration
to reduce cell viability.
To evaluate the protective effects of STX,
cells were pre-treated with STX and then
treated with A𝛽 1-42. STX concentration was
titrated to determine if there was a correlation
between STX concentration and cellular
rescue. When compared to cells treated with
DMSO, there was no consistently observed
statistically significant difference in cell
viability between SH-SY5Y cells treated
with A𝛽 1-42 and STX and those without STX
(Figure 2). During one trial, a statistically
significant difference was observed between
cells treated with A𝛽 1-42 without STX and
those with STX, however, these results have
not been able to be reproduced. This
observation suggests that there may be
confounding sources of error that might be
impeding the experimental process.
Possible explanations for the variation in the
experimental results could be the preparation
of A 𝛽 1-42 itself. The incubation period
suggested for A𝛽 1-42 is 4-7 days. During this
time, A𝛽 1-42 oligomerizes into a clear film,
which will be resuspended in solution.
However, because the film is clear, there is
no good indication that the A 𝛽 1-42 has

oligomerized or can bind to cells. It is also
possible that the time window for aging is
insufficient. A𝛽 1-42 has been allowed to age
for 4 days, but it is possible that increasing
the time allotted for oligomerization would
increase the concentration of A 𝛽 1-42 that
actually forms.
It is also possible that the difference between
cellular concentration of each well has an
allosteric effect on cellular viability. It is
possible that the cellular network produced
between larger concentrations of cells is
better able to resist the toxic effects of A𝛽 1-42.
Decreasing the concentration of cells per well
could potentially decrease the risk of a
cellular network forming a resistance to A𝛽 142, but this is not a change that can be made
in living organisms, and therefore might
decrease the effectiveness of this model.
We have not yet seen conclusive data that
STX can reproducibly rescue SH-SY5Y cells
from A𝛽 1-42, however, we will continue to
make changes to the experimental
methodology to account for discrepancies in
results gathered between trials.

Figure 1. When cell
viability after A𝛽 1-42
exposure was compared to
cells exposed to 2.5%
DMSO, cell viability
decreased by a statistically
significant amount
(p=0.05). Fig1A shows a
relationship between the
concentration of A𝛽 1-42
and cell viability, while
Fig1B shows that there
was not demonstrate this
correlation. Fig1C showed
that 0.5uM A𝛽 1-42 was
sufficient to decrease cell
viability a statistically
significant amount. Y-axis
of each graph has been
scaled to be proportional
to the cell viability of cells
exposed to 0.5% DMSO.
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Figure 2. When cell viability of STX pretreated cells after A𝛽 1-42 exposure was
compared to cells exposed to 2.5% DMSO,
there was no consistently significant
difference between cells treated with STX and
those without. Fig2A shows the results of an
experiment performed in December 2018. No
statistically significant difference was seen.
Fig2B shows the results of an experiment
performed in January 2019. A statistically
significant difference was seen between cells
treated with STX and those without (p=0.05).
Fig2C shows the results of an experiment
performed in April 2019. No statistically
significant difference was seen.

Literature review
Understanding the pathways involved in the
neuroprotective effects of selective estrogen
receptor modulators is extremely complex.
Several pathways have been identified as
likely candidates for neuroprotection, and
they are not mutually exclusive. E2 is a useful
reference compound, as it has very similar
effects to SERMs in the body. Initiation of
signaling pathways in hypothalamic arcuate
neurons begins when E2 binds to the GqmER and activates G𝛼 q, a G-protein subunit.
G 𝛼 q dissociates from the membrane and
activates phospholipase C (PLC) and initiates
the hydrolysis of phosphatidylinositol 4,5bisphosphate (PIP2). PLC then hydrolyzes
PIP2 into diacylglycerol (DAG) and inositol
1,4,5-triphosphate (IP3). DAG actives protein
kinase C (PKC), which activates adenylate
cyclase VII, which increases cAMP
production and stimulates protein kinase A
(PKA). PKA phosphorylation uncouples the
inhibitory GABAB and µ-opioid receptor
from activation of G-protein coupled, inward
rectifying K+ (GIRK) channels. Activation of
PKA also phosphorylates cAMP-responsive
element binding protein and control gene
expression through the CREB response
element. IP3 activates Ca2+ release from the
endoplasmic reticulum that can activate
calcium-dependent signaling. E2 also has
been found to bind to the nuclear receptors
and activate estrogen response elementdependent transcription (11, 12).
This latter finding highlights the important
difference between E2 and SERMs: SERMs
do not bind to nuclear receptors. This has
been demonstrated in multiple studies.
Indeed, it has been shown that the relative
binding affinity of SERMs was reduced by
about 1 million-fold when compared to E2. In
addition to this, STX has been shown to
activate the G𝛼 q signaling pathway in mice
that lack either ER𝛼, ER𝛽, or both nuclear
receptors (11, 12). This suggests that there
might be other differences between the

behavior of STX and E2 within the cell,
including their neuroprotective pathways.
Compelling evidence has shown that STX
binds to the Gq-mER rather than GPR30 (13,
14). When STX was introduced into neurons
that had the GPR30 genes silenced through
an siRNA treatment, the molecule was still
fully efficacious (8, 15). This suggests that
GPR30 was not essential for the function of
STX within the cell. Similar experiments,
which block the release of G𝛼 from Gq-mER
have been performed after cells were treated
with E2 (13) and showed that blocking the
release of the G-subunit is sufficient to block
the effects of E2 in the cell. Reproduction of
this experiment with STX would be the first
step to understanding the method of action of
STX in the cell.
Inhibition of mitogen activated protein
kinase/extracellular signal-regulated kinase
(MAPK/ERK) pathways as well as
phosphatidylionsitol
3-kinase
(PI3K)
pathways were shown to block the ability of
STX to activate the steroidogenic factor 1
(SF-1) in endometrial cells (15). Inhibition of
ERK was also found to block the effects of
STX in vivo (16).
STX was found to
attenuate the GABAB response in cells, and
the inhibition of GABAB by estrogen was
found to be required for the activation of
PKA intracellularly. In addition to this,
PKC 𝛿 inhibitor was found to block the
function of GABAB in cells treated with E2.
PLC was not found to be an essential
inhibitor of GABAB, but it does not rule out
its possible significance in the STX pathway
(13).
It is possible that each of these pathways,
MAPK/ERK, PI3K, PKA, PLC, or PKC 𝛿
play a role in the effect of STX within the cell.
As each of these pathways are non-genomic,
they are the most likely candidates. It is also
possible that this list is incomplete and that
we do not have enough information about
intracellular kinase pathways to yet answer

this question. The next stage of research will
be to treat neuroblastoma cells with A𝛽, STX,
and each of these inhibitors and measure the
cellular rescue response. Combinations of
these inhibitors would also be interesting, to
explore if more than one of these pathways is
involved in the response initiation of STX.
This is likely, given that this is the case for
E2.
Understanding this mechanism of cellular
rescue will allow us to design more effective
treatments for Amyloid 𝛽 toxicity and
ischemic events. Wider applications to this
research include but are not limited to:
Alzheimer’s disease, Parkinson’s disease,
stroke, and other cerebral vascular accidents.
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